Evercore (EVR) has been downgraded to a Zacks Rank #5 (Strong Sell) as earnings estimates decline sharply and the stock falls 25% year-to-date. FY26 and FY27 EPS estimates have dropped 7% and 6% respectively, while Q3 estimates plunged 23% in one week. Rising Treasury yields above 5.3% and higher interest rates threaten investment banking activity and dealmaking, pressuring the firm's advisory and underwriting revenue.

Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with frontline data showing 100% overall survival at eight weeks versus historical 20-30% mortality rates.

Houlihan Lokey (HLI) shares have declined 21.3% year-to-date due to two disappointing quarters, a 24% revenue drop in Corporate Finance, and a 54% decline in technology-related revenues. While the company maintains record backlog and a diversified business model, earnings estimates remain under pressure with a consensus decline of 8.3% expected. Analysts recommend avoiding the stock until operating trends stabilize.

Treasury Secretary Scott Bessent announced an expansion of the Treasury's bond repurchase program from $2 billion to at least $4 billion of longer-dated bonds to ease long-term yields. However, this move could undermine Fed Chair Kevin Warsh's hawkish stance on inflation control, potentially creating confusion about whether the Treasury or Fed is driving monetary policy. The expanded program may weaken the dollar and lead to higher inflation, while also making it difficult for Warsh to justify raising interest rates.

Sandisk shares dropped 12.54% on Monday amid a broader chip stock pullback. However, major Wall Street analysts remain bullish, with Goldman Sachs raising its price target to $2,200 and Evercore lifting its target to $3,100. Both analysts cite sustained AI-driven demand for memory chips from data center operators as justification for their optimistic outlooks.

Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company focused on blood coagulation disorder treatments, priced its initial public offering at $18.00 per share for 16.75 million shares, raising approximately $301.5 million in gross proceeds. The company's stock is expected to begin trading on Nasdaq under ticker symbol 'COAG' on May 1, 2026, with the offering expected to close on May 4, 2026.

BofA Securities initiated coverage of Evercore (NYSE:EVR) with a Buy rating and $435 price target, calling it the 'best pure-play among boutique investment banks.' The analyst highlights Evercore's high advisory revenue mix (80% of total), strong M&A expertise, and growth potential from franchise expansion. With M&A activity expected to reach record highs in 2026, the firm is positioned for positive earnings revisions.

ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.

Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.

Wall Street analysts predict the S&P 500 could experience significant volatility in 2026, with potential scenarios ranging from a 30% surge to a 30% decline, driven by factors like AI adoption, economic conditions, and potential interest rate changes.

Standard Lithium announced a public offering of 29,885,057 common shares at $4.35 per share, raising $130 million to fund capital expenditures for its lithium projects in Arkansas and Texas.

Sprouts Farmers Market stock has fallen 40% since June, but analysts suggest it may be oversold and poised for a potential rebound ahead of upcoming earnings, citing strong historical performance and technical indicators.